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ABSTRACT
High affinity target-binding aptamers are identified
from random oligonucleotide libraries by an in vitro
selection process called Systematic Evolution of
Ligands by EXponential enrichment (SELEX). Since
the SELEX process includes a PCR amplification
step the randomized region of the oligonucleotide
libraries need to be flanked by two fixed primer bind-
ing sequences. These primer binding sites are often
difficult to truncate because they may be necessary
to maintain the structure of the aptamer or may even
be part of the target binding motif. We designed a
novel type of RNA library that carries fixed seq-
uences which constrain the oligonucleotides into
a partly double-stranded structure, thereby minimiz-
ing the risk that the primer binding sequences
become part of the target-binding motif. Moreover,
the specific design of the library including the use of
tandem RNA Polymerase promoters allows the selec-
tion of oligonucleotides without any primer binding
sequences. The library was used to select aptamers
to the mirror-image peptide of ghrelin. Ghrelin is
a potent stimulator of growth-hormone release and
food intake. After selection, the identified aptamer
sequences were directly synthesized in their mirror-
image configuration. The final 44 nt-Spiegelmer,
named NOX-B11-3, blocks ghrelin action in a cell
culture assay displaying an IC50 of 4.5 nM at 37 C.
INTRODUCTION
Aptamers are highly structured oligonucleotides that can bind
to targets with afﬁnities comparable to antibodies. They are
identiﬁed through an evolutionary selection process called
Systematic Evolution of Ligands by EXponential enrichment
(SELEX) (1,2). The SELEX process comprises alternate
selection and ampliﬁcation steps. Using SELEX, aptamers
have been identiﬁed to a plethora of different target mole-
cules that comprise proteins, peptides or small molecules.
Due to the ability to block strong protein–protein interactions,
aptamers have considerable potential as therapeutics (3,4).
However, in order to use aptamers therapeutically, they
have to be stable in vivo and inexpensive in production.
A widely used approach to stabilize aptamers against
nucleolytic attacks involves the successive introduction of
chemically modiﬁed nucleotides into the sequences (5–7).
An alternative strategy to achieve full biostability at once is
to use oligonucleotides that are composed of mirror-image
nucleotides. Such functional mirror-image oligonucleotides
(L-RNA or L-DNA) are named Spiegelmers (from the
German word ‘Spiegel’ meaning mirror). Spiegelmers can
be identiﬁed through introducing chiral principles into the
SELEX process (8): First, aptamers are selected to bind
to the mirror-image conﬁguration of a given target (D-
polypeptide). The aptamer sequences are then synthesized
in their respective mirror-image conﬁguration to give
Spiegelmers, which consequently bind to the natural conﬁ-
guration of said target molecule (L-polypeptide). Based on
this technique, high afﬁnity Spiegelmers to a variety of
targets have been generated (9).
Besides biological (in)stability, the length of aptamer
sequences is a major issue for further development and
commercial application. This is due to the fact that manufac-
turing of oligonucleotides by standard solid phase synthesis
becomes increasingly inefﬁcient and costly with growing
length of the oligonucleotides.
Conventional nucleic acid libraries consist of a central
randomized region ﬂanked by primer binding sites that are
needed for PCR ampliﬁcation. These ﬁxed sequences com-
prise up to 50% of the total available nucleotides. Therefore,
ﬁrst attempts to truncate the isolated aptamers routinely
encompass cutting off the primer binding sequences. How-
ever, the primer binding sites or segments of them are often
an ‘unwanted’ part of the target-binding domain or they
stabilize the active structure of the aptamer. This can espe-
cially be an issue if aptamers are selected to bind to ﬂexible
targets, such as peptides (10–13) or if very high stringencies
within the selection process are applied so that even the ﬁxed
primer binding sites may be ‘directly included’ into the active
functional sequences. In such cases, truncation of an aptamer
to a reasonable size may be difﬁcult or even impossible.
Therefore, new or improved methods to facilitate the trunca-
tion of aptamers are desirable.
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patent literature by Toole et al. (14), but experimental results
are still lacking. Toole et al. suggested to use a primerless
library and up to 512 different double-stranded DNA mole-
cules that contain the primer binding sequences. This pool
of double-stranded DNA molecules can hybridize up to
four 50- and 30-terminal, undeﬁned nucleotides of the respec-
tive library. Contrary to the contemplated method of Toole
et al., the Tailored-SELEX process (15) envisions four and
six ﬁxed nucleotides at the 50 and 30 end of a primerless
RNA library, respectively. The primer binding sequences
are ligated to the library using three double-stranded mole-
cules (adapters) and removed within the ampliﬁcation proce-
dure without the need of puriﬁcation steps. Tailored-SELEX
has been successfully applied to identify high afﬁnity
oligonucleotides to calcitonin gene-related peptide (15).
In order to combine the beneﬁts of an RNA library without
primer binding sites with the speed of an automated selection
protocol (16), a new type of RNA library was designed. This
dual library can be either used as a full-length library or a
short library without primer binding sites. The single or
repeated use of the short library allows direct identiﬁcation
of short aptamers.
The practicality of the new library design was validated
through an in vitro selection against the mirror-image peptide
target D-ghrelin. Ghrelin is a peripheral hormone that stimu-
lates appetite as well as growth hormone release (17,18). It
plays an important role in the regulation of energy homeo-
stasis and has therefore attracted substantial attention as
potential target in obesity (19) and the Prader–Willi
Syndrome (20).
MATERIALS AND METHODS
Oligonucleotides and peptides
All oligonucleotides were synthesized at NOXXON Pharma
AG using standard phosphoramidite chemistry. Human
L-ghrelin as well as human D-ghrelin modiﬁed with a biotin
group linked via D-lysine and two amino-ethyloxy-ethyloxy-
acetyl groups (ghrelin-D-Lys-AEEAc-AEEAc-biotinyl-OH)
at the C-terminus were purchased from Bachem (Bubendorf,
Switzerland).
In vitro selection
A combinatorial RNA library of  10
15 different molecules
was obtained by enzymatic conversion of 3 nmols of a syn-
thetic DNA library (ssDNA pool that contains a T7 RNA
polymerase (bold) promoter sequence, 50-CTTAGTGA-
TACGCTCGTCGATGTGTGCTGC-N34-GCAGCACCCTA-
TAGTGAGTCGTATTACTCCC-30; forward primer with
T3 RNA polymerase (underlined) and T7 RNA polymerase
(bold) promoter sequence: 50-TCAATTAACCCTCACT-
AAAGGGAGTAATACGACTCACTATAGGGT-30) into
dsDNA which was then in vitro transcribed [80 mM
HEPES/KOH (pH 7.5), 22 mM MgCl2, 1 mM spermidine,
10 mM DTT, 0.12 mg/ml BSA, 4 mM NTPs (Larova, Teltow,
Germany), 1 ml RNaseOUT (Invitrogen, Karlsruhe,
Germany), 0.1 U/ml T3 RNA polymerase (MBI Fermentas,
St. Leon-Rot, Germany) at 37 C for 6–12 h] into RNA
(50-GGGAGUAAUACGACUCACUAUAGGGUGCUGC-N34-
GCAGCACACAUCGACGAGCGUAUCACUAAG-30). This
starting pool was initially labelled with [a-
32P]GTP (Hartmann,
Braunschweig, Germany) during in vitro transcription.
The ﬁrst three selection rounds were performed manually
at 10 mM biotinylated D-Ghrelin as described previously
(21) using the T3 RNA polymerase for in vitro transcription.
The next six rounds were carried out using an automation
system (RoboAmp 4200 E, MWG Biotech, Ebersberg,
Germany) according to the protocol of Eulberg et al. (16),
again using the T3 RNA polymerase for in vitro transcription
to result in the full-length library. The RNA was gel-puriﬁed
(22) after every second selection round. Over the six rounds
of automated in vitro selection the peptide concentration was
decreased down to 33 nM.
From round 10 on, the enriched library was employed as
a short library. Therefore the primer binding sites were
removed before the selection step. After the selection step
the primer binding sites were added to the isolated oligonu-
cleotides by ligation. Within the following ﬁve manual selec-
tion rounds the peptide concentration was reduced to 10 pM.
Similar to the previous selection rounds the selection process
was carried out at 37 C and the binding reaction was done in
solution for 12 h. The complexes of RNA and biotinylated
human D-ghrelin were immobilized for 30 min on the selec-
tion matrix (Neutravidin Agarose or Streptavidin Ultralink
beads; Pierce, Rockford). Non-binding molecules were
removed by washing the matrix with 10 to 25 vol of selection
buffer (16). Bound RNA oligonucleotides were eluted twice
(8 M urea, 10 mM EDTA, 65 C for 10 min and 95 C for
10 min), extracted with phenol/chloroform/isoamyl alcohol,
precipitated with ethanol and dissolved in water.
Ligation and amplification
The ligation reaction was carried out at 25 C for 12 h [not
more than 71.4 nM RNA and 36 U T4 ligase/pmolRNA
(Fermentas, St. Leon-Rot, Germany), 1· ligation buffer
(Fermentas), 5% PEG 4000, 0.5 ml RNaseOUT (Invitrogen,
Karlsruhe, Germany), 20-fold excess of forward adapter
and 10-fold excess of reverse adapter 1 and 2 each]. The adap-
ters are double-stranded oligonucleotides: forward adapter
[forward ligate, (RNA: 50-GGGAGUAAUACGACUCA-
CUAUA) plus forward bridge (DNA: 50-GCACCCTATAGT-
GAGTCGddT-30) with 20,30-dideoxythymidine at the 30 end],
reverse adapter 1 [reverse ligate 1 (DNA: 50-pACATCGAC-
GAGCGTATCACTAAddG-30,5 0-phosphorylated and a 20,30-
dideoxyguanosine at the 30 end) plus reverse bridge 1 (DNA:
50-CTTAGTGAUACGCTCGTCGATGUGTGCTG-30 with
two incorporated uridines] and reverse adapter 2 [reverse
ligate 2 (DNA: 50-pCATCGACGAGCGTATCACTAAddG-
30,5 0-phosphorylated and a 20,30-dideoxyguanosine at the 30
end) plus reverse bridge 2 (DNA: 50-CTTAGTGAUACGC-
TCGTCGAT-GIGTGCTddG-30) with the two incorporated
ribonucleotides uridine and inosine, respectively].
The reverse transcription reaction was carried out at
a ﬁnal RNA concentration of not more than 30 nM for
20 min at 51 C and 10 min at 54 C[ 8mM reverse primer
(50-CTTAGTGAUACGCTCGTCGATGUGT) with two
incorporated uridines, 1· ﬁrst strand buffer (Invitrogen),
0.5 M betain (Sigma–Aldrich, Steinheim, Germany),
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script reverse transcriptase II (Invitrogen), 10 mM DTT].
The cDNA was directly transferred into the PCR [not more
than 5 nM cDNA, 1· PCR-buffer (Roche), 3 mM forward
primer, 3 mM reverse primer, 0.2 mM dNTPs (Larova),
0.05 U/ml Taq DNA Polymerase (Roche, Mannheim,
Germany), 2.5 mM Mg
2+, 0.5 M betain, annealing tempera-
ture at 65 C, 7–17 cycles]. The cleavage of the PCR reverse
strand was done by alkaline ﬁssion of the ribonucleotides
[310 mM (ﬁnal) NaOH, 10 min at 95 C, neutralization with
HCl, buffered with 0.1 mM (ﬁnal) sodium acetate].
The PCR product was ethanol precipitated before in vitro
transcription in 80 mM HEPES/KOH (pH 7.5), 22 mM
MgCl2, 1 mM spermidine, 10 mM DTT, 0.12 mg/ml BSA,
4 mM NTPs (Larova), 32 mM 50-GMP (Sigma, Taufkirchen,
Germany), 1 ml RNaseOUT (Invitrogen), 0.1 U/ml T7 RNA
polymerase (Stratagene, La Jolla) at 37 C for 6–12 h. The
transcribed RNA was gel-puriﬁed (22) and radioactively
labelled [2 mM RNA, 1· exchange buffer (Invitrogen),
[g-
32P]ATP (Hartmann, Braunschweig, Germany), 1 U/ml
T4 Polynucleotide Kinase (Invitrogen)]. The enriched library
from round 16 was ligated and PCR-ampliﬁed before cloning
and sequencing at AGOWA (Berlin, Germany).
Competition assay
Radiolabeled aptamer NOX-B11 (2 pmols) was denatured for
3 min at 95 C in selection buffer [20 mM Tris, 150 mM
NaCl, 5 mM KCl (pH 7.4) was adjusted at 37 C] without
Ca
2+ and Mg
2+, folded by addition of these ions to a ﬁnal
concentration of 1 mM at 37 C. A total of 20 nM radio-
labelled NOX-B11 and 40 or 200 nM of the unlabelled
aptamers were incubated with 20 nM biotinylated human
D-ghrelin for 1 h at 37 C. A constant amount of neutravidin
agarose was added for 30 min. The neutravidin agarose was
sedimented, the supernatant removed, the matrix washed and
the ratio of bound radio-labelled NOX-B11 was determined
by measuring the radioactivity using a szintillation counter
(Beckman Coulter LS6500).
Bioassay
Stably transfected CHO-cells expressing the human ghrelin
receptor GHS-R1a (Euroscreen, Gosselies, Belgium) were
seeded with 5–7 · 10
4 cells per well in a black 96-well
plate with clear bottom (Greiner, Frickenhausen, Germany)
and grown overnight at 37 C and 5% CO2 in UltraCHO
medium (Cambrex, Verviers, Belgium) containing 100 U/ml
penicillin, 100 mg/ml streptomycin, 400 mg/ml geneticin and
2.5 mg/ml fungizone. Spiegelmers were incubated for 15 to
60 min with bioactive human ghrelin in UltraCHO medium
containing 5 mM probenecid and 20 mM HEPES (CHO-
U+)a t3 7  C in a 0.2 ml low proﬁle 96-well plates. Cells
were washed once with 200 ml CHO-U+, loaded with 50 ml
0.08% pluronic 127, 10 mM ﬂuo-4 indicator dye solution
(Molecular Probes, Leiden, The Netherlands) in CHO-U+,
and incubated for 60 min at 37 C. Thereafter, cells were
washed three times with 180 ml CHO-U+. A total of 90 ml
CHO-U+ were added per well and cells stimulated with
10 ml of the preincubated Spiegelmer-ghrelin mixture.
Fluorescence was measured at an excitation wavelength of
485 nm and an emission wavelength of 520 nm in a Fluostar
Optima multidetection plate reader (BMG, Offenburg,
Germany). For each well the difference between the maxi-
mum ﬂuorescence and the base line value was determined
and plotted against ghrelin concentration or, in Spiegelmer
inhibition experiments, against concentration of Spiegelmer.
The half maximum effective concentration (EC50) or inhibi-
tion constants IC50 were read from the graphs.
RESULTS
Library design for short and full-length libraries
with a shared PCR product
The dual library that can be either used as full-length library
or as short library was constructed with a randomized region
of 34 nt ﬂanked by seven ﬁxed nucleotides on each side
which can form a double stranded structure (Figure 1). The
primer binding sequences are designed to partially hybridize
with each other. Both structural pre-settings have the function
to minimize potential interactions of the primer binding sites
with the randomized region. In addition to the seven ﬁxed
nucleotides at the 50 end of the short library, two ﬁxed
dangling nucleotides are added to improve the yield of the
ligation reaction (after the selection step) while selecting
with the short library.
The forward (or ‘plus’) strand of the PCR product includes
a tandem of two different RNA polymerase promoters at the
50 end, the T3 and T7 RNA polymerase promoter, res-
pectively. Both promoters encompass part of the sequence
of the forward primer. The annealing sequence of the reverse
primer is located at the 30 end of the forward strand.
In the reverse (or ‘minus’) strand of the PCR product, two
ribonucleotide cleavage sites are incorporated by the reverse
primer: one is located directly upstream of the ﬁxed sequence
(7 nt) and the other in the middle of the reverse primer
sequence. Two cleavage sites ensure that potential re-
hybridization of the fragments or read-through of the RNA
polymerase is avoided. Finally, the 30-region of the reverse
strand constitutes the annealing site for the forward primer.
In order to conduct selection with the short library, at ﬁrst
the main part of the reverse primer is removed from the
reverse strand of the PCR product by alkaline hydrolysis at
the ribonucleotides. Secondly, in vitro transcription is carried
out using T7 RNA polymerase. The resulting RNA transcripts
start directly after the T7 promoter sequence and end with the
7 nt ﬁxed sequence of the 30 end. An 8-fold excess of the
initiation nucleotide guanosine monophosphate in the tran-
scription reaction leads nearly quantitatively to a 50-terminal
monophosphate which is essential for the ligation reaction
afterwards.
On the other hand, selection with the full-length library
only requires transcription of the PCR product with T3
RNA polymerase. Here, the transcripts begin directly after
the T3 promoter and end with the reverse primer binding site.
The T3 as well as the T7 RNA polymerases are known
to add non-templated nucleotides to up to 50% of the synthe-
sized RNA transcripts in a random fashion (23). These so-
called 30-microheterogeneities consist mainly of one random
nucleotide. Since the amount of these modiﬁed transcripts is
signiﬁcant ( 50%) and the added nucleotides complicate
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products in Figure 1.
Workflow for in vitro selection
Both libraries can be used for in vitro selection. The selected
binding molecules of the full-length library can be directly
transcribed into cDNA, transferred to PCR, and transcribed
into the enriched RNA library by T3 RNA polymerase
(Figure 2). Selection with the short library requires a ligation
step to add the primer sequences for subsequent reverse tran-
scription and PCR. The PCR product is then subjected to an
alkaline hydrolysis step to cleave off the primer binding site
of the reverse strand before transcription with T7 RNA poly-
merase generates the enriched short library for the next round
of selection (Figure 2).
The design of the libraries also allows to switch very easily
on the level of the PCR between the short and full-length
library and vice versa (Figure 2). Employing the short library
within the selection scheme in at least one selection round
should make sure that the binding characteristics of the
selected aptamers are independent of the primer sequences.
Ligation of the short library
In order to conduct the selection with the short library the
primer binding sequences need to be added for subsequent
PCR ampliﬁcation. Based on a technique already published
for Tailored-SELEX (15), a ligation strategy with adapter
molecules and highly concentrated T4 DNA ligase was devel-
oped (Figure 3).
Three different adapter molecules for the ligation reactions
were designed. The ‘forward adapter’ for the 50-ligation con-
sists of the ‘forward ligate’ and the ‘forward bridge’. The 30-
ligation requires the ‘reverse adapter 1’ which consists of the
‘reverse ligate 1’ and the ‘reverse bridge 1’ for the ligation of
N-transcripts (Figure 3A). To accommodate the problem of
30-microheterogeneities the ‘reverse adapter 2’, consisting
of the ‘reverse ligate 2’ and the ‘reverse bridge 2’, permits
the 30-ligation of N+1-transcripts (Figure 3B).
During the 50-ligation reaction the forward ligate of the
forward adapter is added to the 50 end of the short library.
The forward ligate contains the T7 RNA polymerase promot-
ers upstream of the ligation site. Six nucleotides at the 50 end
of the forward bridge are complementary to the ﬁrst 6 nt of
the 50-ﬁxed region (9 nt) of the short library so that a directed
ligation of the forward adapter can be achieved. To reduce the
risk that the forward bridge interferes with cDNA synthesis,
it was kept to a minimal but sufﬁcient length of 19 nt.
Moreover, it is blocked at its 30 end by the introduction of
a terminal 20,30-dideoxynucleotide.
The reverse ligates of the reverse adapters restore the
reverse primer binding sequence in the 30-ligation reaction.
Figure 1. Design of the shared PCR product that leads to the short (A) and full-length (B) RNA libraries. The PCR product serves as a shared template for
generating both the short and the full-length library. Tandem promoter sequences for the T3 and T7 RNA polymerase, respectively, are located at the 50 end of the
forward strand (F) and are part of the forward primer at the same time. The integration of the reverse primer that contains two ribonucleotides, introduces the
(necessary) cleavage sites for alkaline hydrolysis of the template for synthesis of the short library. (A) To employ the short RNA library for the selection step, the
reverse strand of the PCR product is cleaved by alkaline hydrolysis at the positions of the ribonucleotides so that the main part of the reverse primer is removed
from the transcription template. The use of the T7 RNA polymerase ensures that transcription starts directly after the T7 promoter to generate the short RNA
library. An excess of guanosine monophosphate in the transcription reaction establishes a monophosphate at the 50 end that is essential for the template-directed
ligation of the forward primer after the selection step. (B) To employ the full-length RNA library for the selection step, the in vitro transcription is carried out
utilizing T3 RNA polymerase. As a consequence, the library contains the full sequence of the T7 RNA promoter at the 50 end. Both polymerases add to their
respective transcripts partially non-templated single nucleotides (30-microheterogeneities) so that the transcribed libraries result in N- and N+1 mixtures,
indicated by an additional ‘N’. prom.: promoter; nt: nucleotides; fp-bs: forward primer binding site; rp-bs: reverse primer binding site.
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ligate 1 is added to the 30-ﬁxed nucleotides of the short
library. Since the reverse ligate 1 is the phosphate donor
in the ligation reaction, it carries a monophosphate at its
50 end; the 30 end is blocked by a 20,30-dideoxynucleotide to
avoid unwanted extension reactions. The reverse bridge 1 is
the template for the directed ligation, whereby 6 nt are com-
plementary to the 30-ﬁxed region. Additionally, the reverse
bridge 1 also serves as reverse primer during reverse tran-
scription and PCR. Thus, comparable to the reverse primer,
two ribonucleotides are incorporated into the reverse bridge
1 to allow site-directed cleavage of the PCR product.
The reverse adapter 2 is necessary for the ligation of the
N+1-transcripts. Due to the additional nucleotide at the 30
end of the N+1 transcripts, the reverse ligate 2 lacks the
ﬁrst 50-nucleotide compared to reverse ligate 1. At the same
time the reverse bridge 2 carries at the complementary posi-
tion inosine instead. Inosine is a universal nucleobase
analogue that can form a base pair with any nucleobase of
the N+1-position of the N+1-transcript. Using this design of
reverse adapter 2, the reverse primer binding site can be
successfully ligated to N+1-transcripts as well. Similar to
the reverse ligate 1 the reverse ligate 2 was blocked with
a2 0,30-dideoxynucleotide to prevent potential extension of
the 30 end.
The functional design of the adapter molecules and the
optimized reaction conditions permit to directly add the
ligation products to the reverse transcription reaction without
any further puriﬁcation. Therefore, the reverse transcription
and the following PCR can be carried out under the same
conditions as the reactions with the full-length library.
Indeed, the resulting PCR products of the short as well as
the full-length library are indistinguishable, so that the PCR
product can be used either to continue with a short library
or a full-length library selection.
The efﬁciencies of the respective ligation reactions was
determined using radioactively labelled RNA transcripts
(Figure 3C). As expected, the 50-ligation of the forward ligate
usually produces acceptable ligation yields in the range of
 80% due to the two 50-dangling nucleotides (Figure 3C,
lane a). On the other side, the sterically less accessible
30 end only generates  30% (Figure 3C, lane b) of the 30-
ligation product. However, if the ligation reactions are carried
out in parallel so that both forward and reverse adapters are
present in equimolar concentrations, the overall ligation
yield is markedly improved (Figure 3C, lane c).
In vitro selection against D-ghrelin
Overall, 18 rounds of in vitro selection against human
D-ghrelin were carried out. The selection step was continu-
ously performed at 37 C. During the ﬁrst nine rounds, the
full-length library was used; the initial three rounds were con-
ducted manually, whereas the other six rounds were executed
using a robotic system as described by Eulberg et al. (16). In
order to increase the selection pressure, the initial peptide
concentration of 1 mM was decreased to 33 nM in round
9 (see Supplementary Data).
Starting with round 10, in vitro selection was carried out by
employing the short library. Due to the restriction of limited
reaction volumes to be handled by the robotic system (up to
100 ml), the selection rounds were performed manually again
in a reaction volume of up to 50 ml (starting with round 10 at
a peptide concentration of 1 nM). The selection pressure was
further increased by decreasing the peptide concentrations to
10 pM in rounds 17 and 18 (Figure 4). Since the signal to
noise ratio in round 18 started to deteriorate, the PCR product
resulting from selection round 16 was cloned and sequenced.
In 19 out of 23 clones, an extension of 6 nt compared to the
length of the starting library was observed (Figure 5). Three
conserved motifs are indicated by the background colours
(blue, yellow and red). By sequence alignment, two families
with one common motif (red) were identiﬁed. The red motif
is already described as a sequence involved in ghrelin-
recognition as reported for the Spiegelmer NOX-B11 (21).
Firstly, all new sequences were synthesized as aptamers and
ranked in a competition assay with NOX-B11 for their ghre-
lin binding potency. The clones showed similar or improved
binding characteristics (data not shown). The best clones
Figure 2. The short (A) and full-length (B) library and the workflow for
in vitro selection. Both variants of the dual RNA library differ in the absence
[(A); short library] or presence [(B); full-length library] of the primer binding
sites. The random region, depicted as a huge loop structure, is clamped by
seven terminal base pairs. (A) In order to amplify the short library after the
selection step, the primer binding sites are added by a template-directed
ligation strategy. The two dangling nucleotides at the 50 end improve the
ligation yield; the 50-terminal nucleotide is monophosphorylated. Subsequent
to ligation the RNA is reverse transcribed and amplified by PCR. The PCR
product is a shared template between both libraries and can be switched to
(B). Ribonucleotides within the reverse primer permit the cleavage of one
strand of the PCR product by alkaline hydrolysis. The following transcription
with T7 RNA polymerase regenerates the (fully truncated) short library. (B)
In order to amplify the full-length library, the isolated RNA sequences are
reverse transcribed and amplified by PCR. As described under (A), the PCR
product is a shared template that can be switched to (A). To transcribe the
RNA for the next round of selection with the full-length RNA library, the
dsDNA is transcribed using T3 RNA polymerase.
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determined in cell culture experiments (Figure 5). Sequence
NOX-F1 turned out to be the best binding molecule and
was therefore subjected to further modiﬁcations. First,
NOX-F1 could be truncated at the 50 end by 6 nt; in addition,
a hexa-loop of a potential hairpin structure (within the yellow
motif) was bridged with a hexaethylene glycol linker (L)
(24). Both modiﬁcations did not compromise the binding
potency.
Ghrelin inhibitory characteristics of
Spiegelmer NOX-B11-3
NOX-F1-trunc was synthesized as a mirror-image RNA oligo-
nucleotide, and the Spiegelmer was named NOX-B11-3. To
determine its potency to inhibit ghrelin action, NOX-B11-3
was tested in a cell culture system using CHO cells that
stably express the GHS-R1a (growth hormone secretagogue
receptor 1a). Different concentrations of NOX-B11-3 were
analyzed to inhibit activation of the GHS-R1a by 2 nM ghre-
lin at 37 C. The readout parameter was the mobilization of
intracellular Ca
2+. NOX-B11-3 inhibits ghrelin-mediated
activation of the GHS-R1a resulting in a half-maximum
inhibitory concentration (IC50) of 4.5 nM (Figure 6). Thus,
the potency of NOX-B11-3 under 37 Ci s 5-fold higher
than the potency of NOX-B11 which was analyzed under
the same assay conditions (Figure 6).
DISCUSSION
Standard in vitro selection experiments are carried out with
oligonucleotide libraries that contain a central randomized
region, ﬂanked by primer binding sites (25). To facilitate
chemical synthesis and to reduce synthesis costs, the resulting
aptamers are usually truncated to minimal target binding
Figure 3. Template-directed ligation of the short RNA library. The cartoon (A and B) presents the structural designs of the short RNA library (N- and N+1-
transcripts) and the double-stranded adapters which consist each of a ligate and a bridge. The randomized region (34 nt) is flanked by seven nucleotides that can
form base pairs (see Figure 1), where upon the 50 end carries two additional fixed nucleotides. Six nucleotides at both ends of the library serve as hybridization
sites for the forward bridge and the two reverse bridges. The uridines (U) and the inosine (I) in the reverse bridge 1 (A) and 2 (B), respectively, introduce the
alkaline fission sites into the primer binding site. The forward bridge, the reverse ligates 1 and 2 additionally contain a 30-terminal 20,30-dideoxynucleotide (30-H)
to prevent mispriming during PCR. Up to 50% of all transcripts are N+1-transcripts (B) that contain a non-coded nucleotide at the 30 end. In order to ligate primer
binding sites to these molecules as well, the reverse adapter 2 was designed. It comprises the reverse ligate 2 i.e. 1 nt shorter at its 50 end than ligate 1, and reverse
bridge 2 that offers the universal base inosine (I) for hybridization to the non-coded nucleotide in the N+1 position of the transcript. The autoradiogram (C)
exemplarily shows the results of the template-directed ligation. While ligation yield of the forward adapter to the 50 end of the RNA molecules was acceptable
(lane a), the ligation of the two reverse adapters 1 and 2 to the 30 end of the library was with  33% quite insufficient (lane b). However, in the case that both
forward and reverse adapters are present in equimolar amounts at the same time, the overall ligation yield was markedly improved (lane c). FA: forward adapter;
RA-1: reverse adapter 1; RA-2: reverse adapter 2; forw: forward; rev: reverse; prom: promoter; nt: nucleotides.
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sites are ﬁxed sequences and ought to be without any further
function, these parts of the oligonucleotides are the preferred
choice to be cut off. However, the primer binding sites or
segments of themselves may often be necessary to stabilize
the overall structure of the aptamers or even become integral
part of the target binding motif (10,26). This phenomenon
especially appears if aptamers (and Spiegelmers) are directed
to bind to structurally ﬂexible targets that usually require
a rigid binding partner (27). Thus, it is not surprising that
only a limited number of oligonucleotides that were gener-
ated by conventional in vitro selection techniques to bind to
small peptides comprise <50 nt (10–13,15,16,21,28).
Only few technical approaches address the problem to
implement steps or techniques within the SELEX process
that lead to readily truncatable aptamers. They are mainly
described in the patent literature and include the blocking
of primer binding sites by hybridization of complementary
oligonucleotides during the selection step (29), ligation
strategies that restore primer binding sites of primerless
libraries before each selection step (14,15,29), and ‘ﬁshing’
of primerless sequences using full-length (primer-bearing)
complementary strands (29). The idea of ‘ﬁshing’ was also
used by Boiziau & Toulme ´ to identify fully 20-O-methyl-
aptamers (30).
The Tailored-SELEX approach is based on a ligation strat-
egy for the primer binding site to an RNA library carrying
a small number of ﬁxed nucleotides on both sides of the
randomized region. Compared to a manual selection, only
two additional reaction steps are needed (15). Nevertheless,
an automation protocol for the so-called Tailored SELEX-
process is possible (16) but one selection round requires
approximately one day, which is signiﬁcantly slower than
automation processes that employ conventional protocols
(16,31,32).
We have developed an RNA library design that can be used
in two different constitutions: as a (conventional) full-length
library with primer binding sites or as a short library without
primer binding sites. The library carries seven comple-
mentary (ﬁxed) nucleotides which clamp the randomized
region and constrain the oligonucleotides into a partly
Figure 4. Progress of manual selection rounds (10–18) using the short library.
The histogram shows the progress of the manual in vitro selection carried out
with the short library starting from round 10. The black circles indicate the
peptide target concentration offered in the respective selection round. In each
selection round equal amounts of radio-labelled RNA were incubated with the
respective peptide concentrations and with pure selection matrix as a control
in order to verify the specific enrichment of binding sequences versus
unspecific binding. The fraction of RNA specifically binding to the target
peptide (white columns) is compared to the fraction of RNA that
unspecifically binds to the selection matrix (grey columns).
Figure 5. Ghrelin-binding sequences. After 16 selection rounds, 23 clones were sequenced. The sequences comprise the fixed nucleotides (nucleotides are
underlined) and the former randomized region. Column (F) indicates the frequency of occurrence of each individual sequence. The obtained sequences were
grouped into two families and compared to the already published ghrelin-binding sequence NOX-B11 (21). Three conserved motifs are indicated by the
background colours (blue, red and yellow). All sequences comprise of a 25 nt motif (red), which was already described as a sequence involved in ghrelin-binding
(21). Firstly, the new sequences were synthesized as aptamers and ranked in a competition assay for their ghrelin binding potency in comparison to aptamer
NOX-B11. All clones showed similar or improved binding characteristics (data not shown). An assortment of clones were synthesized as Spiegelmers and their
IC50-values were determined in cell culture experiments. NOX-F1 turned out to be the strongest binder and this oligonucleotide was further truncated and
modified with a hexaethylene glycol linker (L) to give the final sequence NOX-F1-trunc. n.t. ¼ not tested.
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risk that the primer binding sites become part of the target-
binding motif. However, the use of primer binding sites
forming a double-stranded structure does not guarantee
their truncation without reduction or loss of binding to the
target (F. Jarosch, unpublished data). Therefore, moreover,
the sequence arrangement of the dual library also allows to
carry out the selection step with the short library. In this
case the ﬂanking primer binding sites are removed before
the selection step and added subsequently.
The structural constraints of the RNA library and the
speciﬁc use of the short library within the selection step
facilitate the direct identiﬁcation of short aptamer sequences
without the need of time-consuming or unsuccessful trunca-
tion experiments. However, in order to limit potential losses
of valuable target binding sequences due to additional enzy-
matic steps, in early selection rounds only the full-length
library is employed. Furthermore, the full-length library
allows the use of a faster (automated) selection protocol
(16). Therefore, the RNA library described herein is primarily
used as full-length library for automated in vitro selection.
After a solid basis of target-binding (full-length) sequences
is achieved (here after nine selection rounds), the selection
protocol is switched to the short library. This switch avoids
enrichment of sequences which functions are potentially
dependent on the existence of primer binding sites.
In contrast to the length of the starting (short) library, most
of the enriched oligonucleotides were extended by 6 nt. Since
the additional nucleotides were integrated into the original
random region, this result may be a consequence of the strin-
gent selection conditions rather than an unwanted side-effect
of the design of the dual library. Nevertheless, all sequences
share a common sequence (shaded in red) that was already
described as a ghrelin-binding motif (21). Ranking experi-
ments revealed that the aptamer sequence NOX-F1 showed
the best potency. The corresponding Spiegelmer of NOX-
F1 was further truncated by cleaving off the six 50-terminal
nucleotides and substituting a potential loop region of 6 nt
by a hexaethyleneglycol linker. The resulting Spiegelmer
NOX-F1-trunc (NOX-B11-3) inhibits activation of the
GHS-R1a receptor displaying an inhibition constant (IC50)
of 4.5 nM at 37 C. Thus, the IC50 of NOX-B11-3 is
 5-fold lower than the IC50 of Spiegelmer NOX-B11 if com-
pared at 37 C.
This data underlines that our devised process using a dual
RNA library delivers high afﬁnity aptamers that can easily be
truncated by cleaving off at least the primer binding sites.
Furthermore, the library design permits an easy integration
into an automated selection protocol. Right now, ghrelin-
inhibitor NOX-B11-3 serves as new lead compound and is
currently being evaluated in preclinical studies for the indica-
tion obesity.
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